Pfizer (PFE)
23.79
+0.00 (0.00%)
NYSE · Last Trade: Apr 30th, 8:07 AM EDT
Via The Motley Fool · April 30, 2025
Via The Motley Fool · April 30, 2025
U.S. stock futures are down Wednesday morning, despite major averages ending up on Tuesday, and the S&P 500 and Dow Jones notching their sixth-straight day in the green, the longest streak for the indexes in months.
Via Benzinga · April 30, 2025
Via Talk Markets · April 30, 2025
Via The Motley Fool · April 30, 2025
Wall Street Climbs as Confidence Dips and Rate Cut Hopes Rise
Via Chartmill · April 30, 2025
The CNN Money Fear and Greed index showed further easing in the overall fear level, while the index remained in the "Fear" zone on Tuesday.
Via Benzinga · April 30, 2025
Via The Motley Fool · April 30, 2025
Pfizer Inc. chief executive Albert Bourla says uncertainty related to higher tariffs on pharmaceutical imports under the Trump administration is discouraging the company from investing in the US.
Via Talk Markets · April 29, 2025
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · April 29, 2025
The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market.
Via Investor's Business Daily · April 29, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · April 29, 2025
Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and oil prices fall as investors await economic data and corporate earnings.
Via Benzinga · April 29, 2025
Via Benzinga · April 29, 2025
Pfizer beats Q1 EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.
Via Benzinga · April 29, 2025
Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 7.8% year on year to $13.72 billion. The company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.7% below analysts’ estimates. Its non-GAAP profit of $0.92 per share was 35.2% above analysts’ consensus estimates.
Via StockStory · April 29, 2025
Pfizer's Q1 2025 results indicate a sound earnings performance, with adjusted EPS surpassing expectations.
Via Talk Markets · April 29, 2025
The company also reported light sales, thanks to declining sales of key products like Eliquis and Ibrance.
Via Investor's Business Daily · April 29, 2025
Things were going great, right until the point when they weren't.
Via The Motley Fool · April 29, 2025
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this week.
Via Benzinga · April 29, 2025
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting other manufacturers.
Via Benzinga · April 29, 2025
Via Benzinga · April 29, 2025
On Monday, the major averages settled on a mixed note as traders adopted a "wait-and-watch" approach following four straight sessions of gains.
Via Stocktwits · April 28, 2025